Antibe Therapeutics Inc(Pre-Merger) ATBPF

Healthcare Biotechnology

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.

GREY:ATBPF - Post by User

Antibe Therapeutics Inc(Pre-Merger) > What you see now

<< Previous

Bullboard Posts

Next >>

Comment by Lookingforclueson Jun 19, 2021 8:40pm

238 Views

Post# 33417376

RE:RE:RE:RE:RE:RE:What you see now

120k.......lack of volume?!
Since I was invested in this Equity/ same time as GUD, there appears to be some 'strange' goings on...with both of them, and Supported by Mugmod/Mugmods/Mr Mugsy and an undetermined number of Positive Posters, on the same Page as the before mentioned.
When this person gets swamped by questions he/she contacts SH., and gets the person banned for a bit.
I came back to these to see how they are doing...Same old..SAME OLDE!

<< Previous

Bullboard Posts

Next >>

NervGen Pharma: Proof that NVG-291 works?